Clinical trial NCT00386516: Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Official title: Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Cancer of the Bile Duct
Gallbladder Cancer
Keywords: cholangiocarcinoma
bile duct
biliary
intra-hepatic
extra-hepatic
gall bladder
cancer
carcinoma
metastatic
metastasis
advanced
recurrent
Lead sponsor: Galectin Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2006-10-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall bladder and bile duct cancer.

Detailed description: Determine the overall response rate (ORR) defined as complete response (CR)rate plus partial response (PR) rate using Response Evaluation Criteria in Solid Tumors (RECIST), as well as the stable disease (SD) rate in subjects with unresectable, locally advanced or metastatic cholangiocarcinoma or other biliary tract tumors treated with GM-CT-01 plus 5-Fluorouracil (DAVFU) at doses of 280 mg/m2 and 600 mg/m2, respectively, during cycles of 4 consecutive days of treatment followed by a 24-day follow-up period.

Eligibility criteria: Inclusion Criteria:

1. 18 years of age or older.
2. Histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease.
3. Prior neo-adjuvant or adjuvant therapy (including radiation therapy) is allowed provided it was completed at least 4 weeks before documented disease recurrence or metastasis.
4. Discontinuation of radiation therapy at least 3 weeks prior to Day 1 of Cycle 1. Radiation therapy will not be allowed while a subject is on study except for palliative radiation therapy to non-target lesions administered following consultation with the Medical Monitor.
5. Prior surgery must have been completed at least 14 days prior to Day 1 of Cycle 1.
6. Nne or more measurable target lesion(s) according to RECIST. Measurable lesion(s) must be outside of previous radiation field or demonstrate clear radiographic progression on serial imaging if within previous treatment field.
7. ECOG performance status less than or equal to 2.
8. Life expectancy greater or equal to 3 months.

Exclusion Criteria:

1. Central nervous system metastasis.
2. Bony metastasis as the sole metastasis.
3. Received prior chemotherapy or anti-angiogenesis agents including bevacizumab or erbitux or radiation therapy other than in a neo-adjuvant or adjuvant setting. No concomitant chemotherapy, anti-tumor biologic therapy, or radiation therapy is allowed.
4. If nitrosoureas or mitomycin C were used as neo-adjuvant or adjuvant therapy, then at least 6 weeks should have elapsed prior to treatment with DAVFU.
5. Active infection that requires treatment with systemic antibiotic, anti- fungal. or anti-viral therapy.
6. Congestive heart failure (Class III or IV in the NYHA functional classification system) or any other medical condition that would preclude the IV administration of up to approximately 200 mL of fluid over 30-60 minutes.
7. Unresolved biliary tract obstruction.
8. Known or clinically suspected infection with HIV.
9. Subject has a known intolerance to 5- FU.

Primary outcomes:
measure: Objective response rate (ORR) defined as complete response (CR) rate plus partial response (PR) rate using Response Evaluation Criteria in Solid Tumors (RECIST)
timeFrame: When 18 valuable patients have completed 2nd CT
measure: Stable disease (SD) rate and progression-free survival (PFS) times
timeFrame: When 18 valuable patients have completed 2nd CT
Secondary outcomes:
measure: Safety, tolerability and Quality of Life (QoL)
timeFrame: Any patient completed a drug treatment
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan, Comprehensive Cancer Center
state: Michigan
city: Cincinnati
country: United States
facility: Barrett Cancer Center
state: Ohio
Study officials:
References: